Two molecules. Two completely different mechanisms. Two radically different timescales. Yet ketamine and psilocybin are producing the most significant breakthroughs in depression treatment since the invention of SSRIs — and the evidence suggests they may be heading toward clinical coexistence rather than competition.
The Mechanisms Are Completely Different
Ketamine and psilocybin reach similar therapeutic destinations through opposite neurochemical routes. Ketamine is an NMDA receptor antagonist — it blocks a glutamate receptor and triggers a rapid cascade that includes AMPA receptor activation, BDNF release, and synaptogenesis in the prefrontal cortex. The effect is fast, dramatic, and relatively short-lived without repeat dosing. The brain is essentially forced into a state of rapid synaptic repair.
Psilocybin (via its active metabolite psilocin) is a 5-HT2A receptor agonist — it activates serotonin receptors and produces a profound reorganisation of brain network connectivity, particularly disrupting the default mode network (DMN). The process is slower, phenomenologically rich, and appears to produce more durable neuroplastic changes that persist long after the drug has cleared the body. Where ketamine repairs synapses, psilocybin appears to restructure the patterns those synapses form.
This mechanistic difference is not academic. It predicts everything that follows: the timing of effects, the durability of response, the side effect profile, the appropriate patient population, and the therapeutic context required for each.
Speed: Hours vs Weeks
Ketamine’s most clinically remarkable property is its speed. In the landmark Murrough et al. (2013) randomised controlled trial — the first multi-site ketamine RCT for major depression — 64% of participants showed a meaningful response within 24 hours of their first infusion. For patients in acute suicidal crisis, this speed is not a convenience. It is the entire clinical rationale.
Psilocybin does not work this way. The acute session itself may produce immediate mood shifts — many participants report a lifting of depression that begins within the session. But the robust, sustained antidepressant effect in controlled trials appears to consolidate over 1–4 weeks post-session as neural reorganisation and psychological integration occur. Carhart-Harris et al. (2021) found that at 6 weeks post-treatment, the psilocybin group showed significantly greater remission than escitalopram — but the full picture emerges over weeks, not hours.
The clinical implication is clear: ketamine is the acute intervention, psilocybin is the transformational one. A patient in suicidal crisis needs ketamine. A patient seeking lasting relief from chronic treatment-resistant depression may need psilocybin.
Duration of Effect: 2 Weeks vs 3+ Months
This is where the comparison becomes most clinically significant. Ketamine’s antidepressant effect, while powerful, is typically short-lived. The standard esketamine (Spravato) protocol — the FDA-approved intranasal formulation — requires twice-weekly administration for the first month, then weekly maintenance. Many patients require indefinite ongoing treatment to sustain response. Discontinuation frequently leads to relapse within weeks.
Psilocybin’s durability profile is fundamentally different. In the COMPASS Pathways Phase 2b trial (Goodwin et al., 2022), the 25mg psilocybin group showed sustained MADRS score improvements at 12 weeks post-treatment — from a single dose in a single session. Davis et al. (2021) found that psilocybin treatment for MDD showed sustained remission at 1, 3, and 6 months post-treatment in 71% of participants. Some patients in the Johns Hopkins smoking cessation trials showed sustained effects at 5-year follow-up.
The neuroplasticity window hypothesis (Carhart-Harris, 2021) offers an explanation: psilocybin does not merely alter synaptic strength — it opens a period of enhanced brain plasticity during which deep psychological patterns can be revised. If the integration work is done during this window, the changes appear to persist as stable new neural architectures rather than temporary pharmacological effects.
Regulatory Status: Approved vs Investigational
Esketamine (Spravato) received FDA approval in March 2019 for treatment-resistant depression — the first genuinely novel antidepressant mechanism in decades. It is available via a REMS (Risk Evaluation and Mitigation Strategy) program at certified healthcare settings, where patients must be monitored for two hours post-administration due to dissociation risk. Racemic ketamine infusions (IV) remain off-label but are widely available through ketamine clinics, typically at $400–800 per infusion with no insurance coverage.
Psilocybin remains a Schedule I controlled substance at the federal level in the United States, with no approved indication. COMPASS Pathways’ COMP360 (synthetic psilocybin) received FDA Breakthrough Therapy Designation in 2018. Usona Institute’s psilocybin program received the same designation in 2019. Oregon became the first US state to legalise therapeutic psilocybin access in 2020 (Measure 109, implemented 2023). Colorado followed in 2022. Federal approval, if it comes, is likely 2026–2028 at earliest.
The regulatory gap means patients currently seeking ketamine can access it legally and relatively easily. Patients seeking psilocybin must either wait, travel to Oregon/Colorado, or access it outside the formal medical system — a situation that carries both legal and safety risks.
The Inner Work Demands the Right Foundation
Intentional altered states require preparation, container, and integration. OOTW psilocybin products are formulated for those who approach this work with seriousness — and understand what the neuroplasticity window demands.
Shop OOTW Psilocybin →The COMPASS 2022 vs Murrough 2013 Trial Comparison
Placing the two landmark trials side by side reveals the full contrast. Murrough et al. (2013) enrolled 72 participants with treatment-resistant MDD in a crossover design comparing ketamine to midazolam (active placebo). Response rate at 24 hours: 64% for ketamine vs 28% for midazolam. Mean MADRS reduction: 14.8 points vs 3.0 points. Duration of effect: approximately 2 weeks before symptom return in most responders.
Goodwin et al. (2022) enrolled 233 participants across 22 sites comparing three doses of psilocybin (1mg, 10mg, 25mg). Response at 3 weeks: the 25mg arm showed mean MADRS reduction of 12.0 points above the 1mg control. At 12 weeks, 71% of the 25mg group maintained a clinically meaningful response. Serious adverse events were low across all arms. The key difference from ketamine: the 25mg group maintained their response at 3 months from a single session.
Neither trial is the final word. The ketamine trial was small and crossover; the psilocybin trial lacked an inert placebo and faced functional unblinding. But the direction of evidence is consistent: ketamine leads on speed and acute response, psilocybin leads on durability and depth of effect.
Side Effect and Risk Profiles
Ketamine’s primary risks are dissociation (which occurs in virtually all patients and is dose-dependent), cardiovascular stimulation (elevated heart rate and blood pressure), and potential for misuse in recreational doses. Bladder toxicity has been documented with heavy recreational use but is not typically seen at therapeutic doses. The REMS program exists specifically because of dissociation risk and the potential for driving impairment post-infusion.
Psilocybin’s primary risks are psychological: anxiety, paranoia, and difficult experiences that can be distressing during the session. At clinical doses under proper therapeutic support, these events are typically manageable. Physiological risk is low — psilocybin has no known lethal dose in humans and no significant cardiovascular toxicity at therapeutic doses. The absolute contraindications (personal or family history of psychosis or schizophrenia) are clearly defined in all trial protocols.
The risk profiles suggest different patient selection criteria. Patients with cardiovascular disease may not be ideal ketamine candidates. Patients with personal or family psychiatric history of psychosis are contraindicated for psilocybin. Patients with active substance use disorder may face different risk-benefit calculations for each.
Which Patients Benefit from Which
The emerging clinical consensus suggests these are complementary rather than competing treatments, targeting different points in the patient journey and different presentations of depression.
Ketamine’s profile fits: acute suicidal ideation requiring rapid response; treatment-resistant depression with prior multiple medication failures where speed of response matters; patients who are not psychologically ready for the demands of a psilocybin session; patients requiring ongoing maintenance with repeated treatments.
Psilocybin’s profile fits: patients motivated for deep psychological work and willing to engage with preparation and integration; treatment-resistant depression where durability of response is the primary goal; existential distress, trauma, and addiction (where the mystical experience mechanism appears to be central to the therapeutic effect); patients capable of tolerating an immersive 6–8 hour session with transient loss of ordinary consciousness.
A model gaining traction in psychedelic research circles is sequential use: ketamine to rapidly stabilise a patient in acute crisis, followed by psilocybin therapy once the patient is stable enough to engage in the psychological work the session demands. The two mechanisms may be synergistic — ketamine’s rapid synaptogenesis potentially priming the brain for the deeper reorganisation psilocybin produces.
The Cost and Access Problem
Even setting aside the regulatory gap, cost is a significant determinant of who accesses which treatment. Esketamine (Spravato) infusions run $800–$900 per session at a certified clinic, though insurance coverage exists post-FDA approval. A maintenance protocol of weekly infusions costs $40,000–$50,000 per year without coverage. IV ketamine (off-label) is $400–$800 per infusion with no insurance coverage whatsoever.
Psilocybin therapy, once approved, is expected to be expensive — a full therapeutic protocol (preparation + session + integration) might cost $2,000–$5,000. But it is a one-time or infrequent cost, not an ongoing maintenance expense. A single psilocybin session producing 3–6 months of sustained remission compares favourably on cost-effectiveness to indefinite ketamine maintenance, even at premium pricing.
The access equation will depend heavily on insurance coverage decisions once psilocybin receives federal approval. The mental health burden of treatment-resistant depression is significant enough that payers will face pressure to cover evidence-based treatments — as they did, eventually, with esketamine.